P. Zens

Discipline

Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (13)

Co-auteur

Date

Source

Mot-clé

Patients (12) Patients (12) Lungs (11) Treatment (10) Lungs--Cancer (10) thérapie (9) survie (9) Therapeutics (9) Survival (9) Tumors (8) Human beings (8) Cancer (8) Chemotherapy (7) Expression (7) Chemotherapy (7) Tumors (6) cohorte (6) analyse (5) Inhibitors (5) Cases (5) Prognosis (5) Cases (5) Analysis (5) Prognosis (5) protéine (4) biomarqueur (4) cancer (4) Cancer (4) Squamous cell carcinoma (4) Cells (4)

Documents écrit par P. Zens (13) | parle de P. Zens (0)

Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma.
J. Wang et al. (2 nov. 2023)
Patterns of Carbon-Bound Exogenous Compounds Impact Disease Pathophysiology in Lung Cancer Subtypes in Different Ways.
J. Shen et al. (12 sept. 2023)
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
D. König et al. (11 juil. 2023)
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.
C. Barrera et al. (1 juin 2023)
Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors.
E. Kashani et al. (6 avr. 2023)
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.
P. Zens et al.
Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients.
A. Kündig et al.
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.
R. Ding et al. (3 juin 2022)
Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients.
J. Shen et al.
Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
E. Vassella et al.
Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.
T. Losmanova et al. (13 oct. 2021)
A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
P. Zens et al.
Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).
Y. Gao et al. (19 avr. 2021)